从聚(ADP-核糖)聚合酶抑制走向靶向癌症治疗中的DNA修复与DNA损伤应答
该综述梳理了聚(ADP-核糖)聚合酶(PARP)抑制剂在乳腺癌和卵巢癌中的最新临床证据,并探讨其向一线治疗及其他瘤种的扩展;同时评述患者选择方法、PARP抑制剂耐药机制,以及靶向DNA损伤应答(DDR)通路其他成员(如MLH1、ATM、ATR、CHK1/2、DNA-PKcs、WEE1、CDC7、POLQ、RAD51、PARG)的临床前依据与早期临床试验,最后提出最大化DDR靶向治疗机会需解决的挑战。
要点
- PARP是DDR通路中最知名的靶点,已有多种PARP抑制剂获批上市。
- DDR通路涉及约450种蛋白,除PARP外多个靶点正在实验室和临床研究中。
- 综述涵盖PARP抑制剂在乳腺癌和卵巢癌的临床证据、患者选择及耐药机制。
核心结论
- 靶向DDR通路是重要的癌症治疗策略,除PARP外尚有多个DDR成员正被研究,需解决相关挑战以最大化治疗机会。
研究设计与样本
- 综述:回顾PARP抑制剂在乳腺癌和卵巢癌中的最新临床证据,并总结靶向DDR其他成员的临床前依据与早期临床试验。
主要发现
- PARP是DDR通路中最知名的元素,已有多种PARP抑制剂获批。
- DDR通路涉及约450种蛋白,多个其他靶点正在实验室和临床中研究。
- 综述评述了PARP抑制剂的患者选择技术证据并总结了耐药机制。
- 早期临床试验正在研究靶向DNA损伤传感器(MLH1)、损伤信号分子(ATM、ATR、CHK1/2、DNA-PKcs、WEE1、CDC7)或修复效应蛋白(POLQ、RAD51、PARG)的单药或联合方案。
关键数值与推荐
- DDR通路涉及约450种蛋白。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The DNA damage response (DDR) pathway coordinates the identification, signaling, and repair of DNA damage caused by endogenous or exogenous factors and regulates cell-cycle progression with DNA repair to minimize DNA damage being permanently passed through cell division. Severe DNA damage that cannot be repaired may trigger apoptosis; as such, the DDR pathway is of crucial importance as a cancer target. Poly (ADP-ribose) polymerase (PARP) is the best-known element of the DDR, and several PARP inhibitors have been licensed. However, there are approximately 450 proteins involved in DDR, and a number of these other targets are being investigated in the laboratory and clinic. We review the most recent evidence for the clinical effect of PARP inhibition in breast and ovarian cancer and explore expansion into the first-line setting and into other tumor types. We critique the evidence for patient selection techniques and summarize what is known about mechanisms of PARP inhibitor resistance. We then discuss what is known about the preclinical rationale for targeting other members of the DDR pathway and the associated tumor cell genetics that may confer sensitivity to these agents. Examples include DNA damage sensors (MLH1), damage signaling molecules (ataxia-telangiectasia mutated; ataxia-telangiectasia mutated-related and Rad3-related; CHK1/2; DNA-dependent protein kinase, catalytic subunit; WEE1; CDC7), or effector proteins for repair (POLQ [also referred to as POLθ], RAD51, poly [ADP-ribose] glycohydrolase). Early-phase clinical trials targeting some of these molecules, either as a single agent or in combination, are discussed. Finally, we outline the challenges that must be addressed to maximize the therapeutic opportunity that targeting DDR provides.
引用
- Gourley C, Balmaña J, Ledermann JA, et al. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. J Clin Oncol. 2019. PMID: 31050911. doi:10.1200/JCO.18.02050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。